Red blood cell surface sialylated glycoproteins (RBC sialoglycoproteins)

Red blood cell surface sialylated glycoproteins, primarily the glycophorin family (Glycophorin A, B, and C), are major components of the erythrocyte membrane (UniProt: P02724). These proteins are heavily modified with sialic acid-containing oligosaccharides, which provide the red blood cell (RBC) with a strong negative surface charge. This charge, known as the zeta potential, is essential for preventing cellular aggregation and ensuring smooth microvascular circulation (PMID: 2510187). Beyond structural maintenance, these glycoproteins serve as critical receptors for pathogen invasion; for example, Glycophorin A is the primary receptor for the Plasmodium falciparum erythrocyte-binding antigen 175 (EBA-175), a key step in the malaria life cycle (PMID: 11560857). They also harbor the antigens for the MNS blood group system, making them significant in transfusion medicine. In therapeutic development, these glycoproteins are targeted to block viral and parasitic attachment or are exploited as platforms for RBC-hitchhiking to improve the pharmacokinetics of various drugs (PMID: 30356155). Alterations in the sialylation patterns of these glycoproteins are often observed in inflammatory and hematological diseases. Understanding their interaction with both endogenous proteins and exogenous pathogens is vital for developing targeted anti-infective therapies.

Other names

GlycophorinsErythrocyte sialoglycoproteinsSialylated RBC surface proteinsPAS-positive glycoproteinsMNS blood group antigens

Pathogen entry inhibition via competitive binding to sialic acid motifs or enzymatic removal of sialic acid residues (PMID: 11560857); also serves as a substrate for erythrocyte-mediated drug delivery (hitchhiking) to prolong systemic circulation (PMID: 30356155).